You have 9 free searches left this month | for more free features.

Core Binding Factor Acute Myeloid Leukemia

Showing 1 - 25 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Core Binding Factor Acute Myeloid Leukemia, KIT Mutation-Related Tumors Trial in Suzhou (Avapritinib)

Recruiting
  • Core Binding Factor Acute Myeloid Leukemia
  • KIT Mutation-Related Tumors
  • Suzhou, Jiangsu, China
    First Affiliated Hospital of Soochow University
Apr 7, 2023

Core Binding Factor Acute Myeloid Leukemia Trial in Guangzhou (Sorafenib, Idarubicin, Cytarabine)

Recruiting
  • Core Binding Factor Acute Myeloid Leukemia
  • Guangzhou, Guangdong, China
    Department of Hematology,Nanfang Hospital, Southern Medical Univ
May 31, 2022

Core Binding Factor Acute Myeloid Leukemia (CBF-AML) Trial in Milano (Midostaurin)

Recruiting
  • Core Binding Factor Acute Myeloid Leukemia (CBF-AML)
  • Milano, Italy
    Ospedale Cà Granda - Niguarda S.C: Ematologia
Jan 22, 2022

Acute Myeloid Leukemia, Core-Binding Factor Trial in Shanghai (Fludarabine, Cytarabine)

Recruiting
  • Acute Myeloid Leukemia
  • Core-Binding Factor
  • Shanghai, Shanghai, China
    Xianmin Song
May 5, 2022

Multicenter Retrospective Observatory of Acute Myeloid Leukemia

Recruiting
  • Acute Myeloblastic Leukemia Core Binding Factor
  • NOT PROVIDED
  • Amiens, France
  • +25 more
Sep 27, 2021

Acute Myeloid Leukemia (AML) Trial in Austria, Germany (Dasatinib, Cytarabine, Daunorubicin)

Active, not recruiting
  • Acute Myeloid Leukemia (AML)
  • Innsbruck, Austria
  • +53 more
Sep 19, 2022

Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Acute

Recruiting
  • Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11
  • +9 more
  • Houston, Texas
    M D Anderson Cancer Center
Oct 27, 2021

AML, AML With Mutated NPM1, Hematologic Malignancy Trial (Ziftomenib, Fludarabine, Idarubicin)

Not yet recruiting
  • AML
  • +11 more
  • (no location specified)
Aug 14, 2023

Refractory/Relapse Acute Myeloid Leukemia Trial in Kunming (Venetoclax)

Recruiting
  • Refractory/Relapse Acute Myeloid Leukemia
  • Kunming, Yunnan, China
    Department of Hematology,920th Hospital of Joint Logistic Suppor
Mar 28, 2023

Relapsed or Refractory Acute Myeloid Leukemia Trial in Taiyuan (Selinexor, Homoharringtonine, Daunorubicin)

Recruiting
  • Relapsed or Refractory Acute Myeloid Leukemia
  • Taiyuan, Shanxi, China
    Tao Wang
Feb 9, 2023

Acute Myeloid Leukemia Trial in Nanjing (Venclexta 100 MG Oral Tablet)

Recruiting
  • Acute Myeloid Leukemia
  • Venclexta 100 MG Oral Tablet
  • Nanjing, Jiangsu, China
    The First Affiliated Hospital with Nanjing Medical University
Jun 11, 2023

Acute Myeloid Leukemia Trial in Beijing (Azacytidine;Cytarabine;Aclacinomycin;Chidamide;Venetoclax;Granulocyte

Recruiting
  • Acute Myeloid Leukemia
  • Azacytidine;Cytarabine;Aclacinomycin;Chidamide;Venetoclax;Granulocyte colony-stimulating factor
  • "3+7"
  • Beijing, Beijing, China
    Chinese PLA General Hospital
Sep 29, 2023

Relapsed/Refractory Acute Myeloid Leukemia Trial in Beijing

Recruiting
  • Relapsed/Refractory Acute Myeloid Leukemia
  • Azacytidine;Cytarabine;Aclacinomycin;Chidamide;Venetoclax;Granulocyte colony-stimulating factor
  • Best-Available Therapy(BAT) Regimen
  • Beijing, Beijing, China
    Chinese PLA General Hospital
Oct 10, 2023

Acute Myeloid Leukemia, Myeloid Tumor Trial in Seattle (Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Myeloid Neoplasm
  • Biospecimen Collection
  • +9 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Sep 5, 2023

Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia Trial in Seattle (Cladribine, Cytarabine,

Recruiting
  • Acute Biphenotypic Leukemia
  • +11 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Oct 18, 2022

Secondary Acute Myeloid Leukemia Trial in Ann Arbor (Venetoclax, FLAG Protocol)

Not yet recruiting
  • Secondary Acute Myeloid Leukemia
  • Ann Arbor, Michigan
    University of Michigan Rogel Cancer Center
Mar 22, 2023

Relapsed Adult AML, Refractory AML Trial in Milwaukee (Navitoclax Dose Level -1, Navitoclax Dose Level 0, Navitoclax Dose Level

Not yet recruiting
  • Relapsed Adult AML
  • Refractory AML
  • Navitoclax Dose Level -1
  • +10 more
  • Milwaukee, Wisconsin
    Froedtert Hospital & the Medical College of Wisconsin
Aug 17, 2023

Acute Myeloid Leukemia Trial in Seattle (drug, biological, other)

Active, not recruiting
  • Acute Myeloid Leukemia
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Oct 10, 2022

Acute Myeloid Leukemia Trial in Shenyang (rhTPO, Decitabine)

Recruiting
  • Acute Myeloid Leukemia
  • Shenyang, Liaoning, China
    ShengJing Hospital of China Medical University
May 16, 2022

Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome Trial in Duarte (procedure, biological, drug,

Recruiting
  • Acute Lymphoblastic Leukemia
  • +3 more
  • Allogeneic Hematopoietic Stem Cell Transplantation
  • +8 more
  • Duarte, California
    City of Hope Medical Center
Jan 12, 2023

Acute Myeloid Leukemia Trial in Shenyang (rhTPO)

Recruiting
  • Acute Myeloid Leukemia
  • Shenyang, Liaoning, China
    ShengJing Hospital of China Medical University
Feb 17, 2022

Acute Leukemia of Ambiguous Lineage, Acute Myeloid Leukemia, Myeloid Tumor Trial in Seattle (drug, biological, other)

Completed
  • Acute Leukemia of Ambiguous Lineage
  • +2 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Feb 23, 2022

MDS, de Novo, MDS, Secondary, MDS, Previously Treated Trial in Boston (Venetoclax, Azacitidine, Cytarabine)

Recruiting
  • Myelodysplastic Syndromes, de Novo
  • +10 more
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
Jan 23, 2023

Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid

Recruiting
  • Acute Lymphoblastic Leukemia in Remission
  • +11 more
  • Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10
  • +8 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Oct 24, 2022